Red Light HollandCSE: TRIP

Actual: Jul 1, 2025

First psilocybin shipment received by Irvine Labs under US Controlled Substances import permit

Why it matters: DEA-authorized importation of psilocybin for R&D is a significant regulatory milestone. Enables microdosing capsule development, shelf-life validation, and clinical supply manufacturing in the US.

Actual: Nov 1, 2025

Second larger shipment (5kg) of natural psilocybin received by Irvine Labs under 2025 DEA quota; quality issues noted — shipping/customs delays impacted product condition

Why it matters: Scale-up of DEA-authorized imports, though quality degradation during transit highlights the logistical challenges of working with Schedule I substances across international borders.

Actual: Mar 10, 2026

Signed definitive agreement to acquire Filament Health (all-share, ~182M shares issued, RLH shareholders retain ~70%); adds GMP facility in Vancouver, 76 patents (15 families), Health Canada Level 8 Dealer's Licence, supply to 70+ clinical studies; pending Q2 2026 close

Why it matters: Transformative acquisition that would give Red Light Holland actual pharmaceutical manufacturing capability and one of the largest natural psilocybin patent portfolios globally. Filament was near-insolvent (cash below $335K), making this a distressed-asset deal. If completed, RLH transitions from a consumer truffle company to a clinical supply and R&D platform.

Watch next: Q2 2026 acquisition close; integration of Filament GMP facility; first clinical supply contracts